Supriya Lifescience Ltd

Supriya Lifescience Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Supriya Lifescience Ltd has witnessed a significant shift in its technical parameters, moving from a mildly bullish to a bullish trend, signalling renewed momentum in the Pharmaceuticals & Biotechnology sector. Despite a recent day decline of 3.14%, the stock’s technical indicators, including MACD, moving averages, and Bollinger Bands, suggest an improving outlook that investors should closely monitor.

The 50-day moving average has crossed above the 200-day moving average for Supriya Lifescience Ltd, signalling a golden cross on 8 Jun 2026. Yet, the stock declined 3.14% on the day the cross formed, and some monthly indicators remain bearish. This juxtaposition invites a closer examination of the signal’s reliability in the current context.

Supriya Lifescience Ltd experienced a notable decline today, touching an intraday low of Rs 970, reflecting a sharp price correction of 7.47% amid broader market pressures and heightened volatility. The stock underperformed its sector and the benchmark Sensex, marking a reversal after four consecutive days of gains.

While the Sensex closed down 0.65%, Supriya Lifescience Ltd surged 8.07% on 01 Jun 2026, hitting a fresh 52-week and all-time high of Rs 1072.05. This 11.13 percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers signals a distinctly stock-specific rally rather than a market-wide lift.

Supriya Lifescience Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 1 June 2026 by touching an all-time high stock price of Rs.1,013.10. This achievement reflects the company’s robust performance and sustained upward momentum in the market.

With a decisive break above Rs 1,000, Supriya Lifescience Ltd has reached a new 52-week high of Rs 1,013.1 on 1 Jun 2026, marking a significant milestone in its price momentum. This surge comes after four consecutive days of gains, cumulatively delivering a 26.47% return, underscoring the stock’s robust technical trajectory amid a mixed broader market backdrop.

Supriya Lifescience Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 May 2026. While the rating change occurred on that date, the analysis and financial metrics presented here reflect the stock's current position as of 31 May 2026, providing investors with the most up-to-date view of the company’s performance and prospects.

Supriya Lifescience Ltd has delivered a remarkable turnaround in its financial performance for the quarter ended March 2026, registering its highest-ever quarterly revenue and profit metrics. This surge has propelled the company’s financial trend from flat to very positive, signalling renewed investor confidence and robust operational execution within the Pharmaceuticals & Biotechnology sector.

At Rs 968.7, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Supriya Lifescience Ltd locked at its upper circuit of 17.7% on 29 May 2026, with buyers queuing and no sellers willing to part with shares.

With a decisive surge to Rs 944.4 on 29 Jun 2026, Supriya Lifescience Ltd has reached a fresh 52-week high, marking a 73.1% rally from its low of Rs 545.65 over the past year. This milestone is underpinned by a confluence of strong technical signals and sustained price momentum that have propelled the stock well ahead of its sector and the broader market.

Supriya Lifescience Ltd witnessed a robust start to the trading session on 29 May 2026, opening with a notable gap up of 9.78%, reflecting positive market sentiment and strong momentum in the Pharmaceuticals & Biotechnology sector.

Supriya Lifescience Ltd, a key player in the Pharmaceuticals & Biotechnology sector, achieved a landmark by reaching its all-time high price of Rs.928.70 on 29 May 2026. This milestone reflects the company’s robust performance and sustained upward momentum in the stock market.

The Sensex remained flat on 29 May 2026, while Supriya Lifescience Ltd surged 14.09% to touch a new 52-week high of Rs 917.95. This 12.96-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a broad market move.

Supriya Lifescience Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has exhibited a notable shift in price momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s technical indicators present a nuanced picture, with weekly signals suggesting optimism while monthly metrics remain cautious.

Supriya Lifescience Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a recent downgrade in its Mojo Grade from Hold to Sell, the stock’s price action and technical indicators present a complex picture for investors navigating the current market environment.

Supriya Lifescience Ltd has demonstrated a notable shift in price momentum, moving from a sideways trend to a mildly bullish stance, supported by a blend of technical indicators that suggest cautious optimism for investors in this pharmaceuticals and biotechnology small-cap.